Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Biomarkers and prognostic factors for mesothelioma.

Pass HI.

Ann Cardiothorac Surg. 2012 Nov;1(4):449-56. doi: 10.3978/j.issn.2225-319X.2012.10.04. No abstract available.

2.

Biomarkers and prognostic factors for malignant pleural mesothelioma.

Vigneri P, Martorana F, Manzella L, Stella S.

Future Oncol. 2015;11(24 Suppl):29-33. doi: 10.2217/fon.15.317. Review.

PMID:
26638920
3.

Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma.

Tsao AS, Harun N, Fujimoto J, Devito V, Lee JJ, Kuhn E, Mehran R, Rice D, Moran C, Hong WK, Shen L, Suraokar M, Wistuba I.

Ann Diagn Pathol. 2014 Jun;18(3):140-5. doi: 10.1016/j.anndiagpath.2014.02.005. Epub 2014 Feb 20.

4.

Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.

Frischknecht L, Meerang M, Soltermann A, Stahel R, Moch H, Seifert B, Weder W, Opitz I.

J Thorac Cardiovasc Surg. 2015 Jun;149(6):1539-46.e1. doi: 10.1016/j.jtcvs.2015.01.065. Epub 2015 Feb 12.

5.

Inflammation-based prognostic indices in malignant pleural mesothelioma.

Pinato DJ, Mauri FA, Ramakrishnan R, Wahab L, Lloyd T, Sharma R.

J Thorac Oncol. 2012 Mar;7(3):587-94. doi: 10.1097/JTO.0b013e31823f45c1.

6.

Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.

Kadota K, Villena-Vargas J, Nitadori J, Sima CS, Jones DR, Travis WD, Adusumilli PS.

Ann Surg Oncol. 2015 Sep;22(9):3136-43. doi: 10.1245/s10434-015-4374-x. Epub 2015 Jan 22.

7.

Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.

Yamagishi T, Fujimoto N, Nishi H, Miyamoto Y, Hara N, Asano M, Fuchimoto Y, Wada S, Kitamura K, Ozaki S, Kishimoto T.

Lung Cancer. 2015 Oct;90(1):111-7. doi: 10.1016/j.lungcan.2015.07.014. Epub 2015 Jul 30.

PMID:
26259877
8.

Prognostic factors in mesothelioma.

Steele JP.

Semin Oncol. 2002 Feb;29(1):36-40. Review.

PMID:
11836667
9.

Prognostic factors and survival in malignant pleural mesothelioma.

Van Gelder T, Damhuis RA, Hoogsteden HC.

Eur Respir J. 1994 Jun;7(6):1035-8.

10.

[Malignant mesothelioma in Basse-Normandie, a French population study. Descriptive analysis, prognostic factors and survival].

Desoubeaux N, Bouvier V, Gervais R, Galateau-Salle F, Thibon P, Leplumey T, Herbert C, Lecherbonnier Y, Daviet JP, Letourneux M.

Rev Epidemiol Sante Publique. 2001 Dec;49(6):523-9. French.

PMID:
11845101
11.

Prognostic factors in mesothelioma.

Steele JP, Klabatsa A, Fennell DA, Palläska A, Sheaff MT, Evans MT, Shamash J, Rudd RM.

Lung Cancer. 2005 Jul;49 Suppl 1:S49-52.

PMID:
15894403
12.

Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers.

Creaney J, Dick IM, Musk AW, Olsen NJ, Robinson BW.

Biomarkers. 2016 Sep;21(6):551-61. doi: 10.3109/1354750X.2016.1160429. Epub 2016 Mar 24.

PMID:
27009350
13.

A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.

Kataoka Y, Yamamoto Y, Otsuki T, Shinomiya M, Terada T, Fukuma S, Yamazaki S, Hirabayashi M, Nakano T, Fukuhara S.

Jpn J Clin Oncol. 2015 Jun;45(6):562-8. doi: 10.1093/jjco/hyv039. Epub 2015 Apr 2.

14.
15.

A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.

Kadota K, Suzuki K, Colovos C, Sima CS, Rusch VW, Travis WD, Adusumilli PS.

Mod Pathol. 2012 Feb;25(2):260-71. doi: 10.1038/modpathol.2011.146. Epub 2011 Oct 7.

16.

Chemokines involved in the early inflammatory response and in pro-tumoral activity in asbestos-exposed workers from an Italian coastal area with territorial clusters of pleural malignant mesothelioma.

Comar M, Zanotta N, Zanconati F, Cortale M, Bonotti A, Cristaudo A, Bovenzi M.

Lung Cancer. 2016 Apr;94:61-7. doi: 10.1016/j.lungcan.2016.01.020. Epub 2016 Feb 1.

PMID:
26973208
17.

Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor.

Alì G, Boldrini L, Lucchi M, Mussi A, Corsi V, Fontanini G.

J Thorac Oncol. 2009 Mar;4(3):348-54. doi: 10.1097/JTO.0b013e3181989ddb.

18.
19.

A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.

Nowak AK, Francis RJ, Phillips MJ, Millward MJ, van der Schaaf AA, Boucek J, Musk AW, McCoy MJ, Segal A, Robins P, Byrne MJ.

Clin Cancer Res. 2010 Apr 15;16(8):2409-17. doi: 10.1158/1078-0432.CCR-09-2313. Epub 2010 Apr 6.

20.

Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.

Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S.

J Clin Pathol. 2013 Oct;66(10):854-61. doi: 10.1136/jclinpath-2013-201609. Epub 2013 Jul 6. Review.

PMID:
23833051

Supplemental Content

Support Center